Global Orthopedic Regenerative Surgical Products Market by End User (Ambulatory Surgical Centers, Hospitals), by Product (Cell-based, Synthetic, Allograft, Viscosupplements) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

Summary of the Report

Global orthopedic regenerative surgical product market was valued at USD 3.4 billion in 2020. It is expected to grow at a compound annual rate (CAGR of 3.6%) between 2021 and 2028. This market is driven by technological advances, arthritis, other orthopedic conditions, orthopedic surgeries and R&D activities. In April 2021, the Azienda Ospedaliero-Universitaria Consorziale Policlinico in Italy completed a study on Platelet Rich Plasma (PRP) Injections for knee osteoarthritis in adults aged between 40 to 81 years. This is one of many R&D projects that have been registered on the clinicaltrials.gov platform of U.S. National Library of Medicine.

Due to cancellations of elective procedures and disruptions in clinical trials, the COVID-19 pandemic had a negative impact on the orthopedic regenerative surgery market. There was also a low demand and sales. Businesses also faced operational difficulties due to supply chain disruptions and travel restrictions. Stay-at-home protocols, illness, quarantines, business closures, and extended periods of interruption caused by long periods of interruption. For example, the U.S. public health agencies recommended delaying elective surgery to avoid cross-infection and manage coronavirus patients. To avoid exposure to COVID-19 virus, patients also deferred elective surgery.

As movement restrictions decrease, elective surgery is expected to rise as long as the underlying causes are not affected. To help elective surgery be resumed safely, several regulatory bodies have issued guidelines. These guidelines include those of the American Society of Anesthesiologists, American Hospital Association, American College of Surgeons and Association of periOperative Registered Nurses.

Osteoarthritis, a primary cause of disability in the elderly population, is a major driver for the market. The global prevalence of knee osteoarthritis was 16% according to research by the Lancet, which was funded by the National Natural Science Foundation Council of China. The prevalence was higher among those aged 40 or more, and was estimated at 22.9% (or approximately 645.1 million people) in 2020. Due to obesity and sedentary lifestyles, the incidence of osteoarthritis is expected to rise over the forecast period, which will drive the market for orthopaedic regenerative surgery products.

The market for orthopedic regenerative surgery products suffered a 4.0% drop in revenue due to COVID-19

The market is expected to be driven by technological advancements, such as stem cells, viscosupplements and Platelet Rich Plasma therapies. A 2020 survey by the International Journal of Complementary and Alternative Medicine found that 70% of respondents considered regenerative medicines therapies to be positive in treating musculoskeletal issues. Participants who had previously experienced regenerative medicine therapies were more likely to respond positively. Amniox Medical published the results of a retrospective study in November 2020. The findings showed that amniotic membrane/umbilical chord particulate significantly delayed Total Knee Arthroplasty, or TKA, in patients with moderate to severe osteoarthritis.

Product Insights

Viscosupplements dominated the market for orthopedic surgical products in 2020, accounting for 42.7% of the total revenue. This is due to increasing incidences of osteoarthritis and knee pain. Other factors, such as obesity, excess exercise, genetic predisposition and aging, all contribute to knee osteoarthritis. This drives the market for orthopedic regenerative surgery products. Fidia Pharma USA Inc. launched a Hyaluronic Acid-based Viscosupplement-Triluron in the U.S. in December 2019. This product is used to treat osteoarthritic pain. In March 2019, Seikagaku Corporation launched the intra-articular injection HyLink from Seikagaku Corporation in Italy. This product is CE-marked and provides pain relief for 26 consecutive weeks to knee osteoarthritis patients.

Over the forecast period, the allografts market is expected to grow at 3.7%. This is due to the increased use of allografts such as fresh-frozen allografts for men, osteochondral allografts and off-the-shelf soft tissue allografts in orthopedic surgery. JRF Ortho an Allograft Company claims that allografts have several advantages, including a shorter recovery time, faster bone healing, and less complications. The company has distributed more that 20,000 new osteochondral allografts. It focuses on the market for sport medicine.

Application Insights

In 2020, the largest segment for orthopedic regenerative surgical products was joint reconstruction. It accounted for 35.0% of the total revenue. This share can be attributed to increasing surgical procedures, the adoption of regenerative solutions for joint reconstruction, as well as technological advances. Amniox Medical, Inc. offers the Clarix line surgical allografts to be used in orthopedic surgery for various procedures, including trauma and reconstruction, soft-tissue repair, and arthroplasty.

The fastest growth rate for the cartilage and tendon repair market is 3.8%. This is due to the growing use of the product in sports medicine and the increased incidence of trauma cases. The company recorded MACI revenue of USD 94.4 millions for the year ended December 2020, despite COVID-19.

End-user insights

Hospitals dominated the market in orthopedic regenerative surgery products, accounting for 50.4% of the total revenue share in 2020. Hospitals are home to a greater number of orthopedic procedures. For example, the Gelenk Klinik orthopedic hospital in Germany performs approximately 2400 procedures annually and treats more than 24,000 patients each year.

The highest estimated CAGR for the other segment, which includes orthopedic specialty centers and clinics, is 3.7%. This is due to the high use of orthopedic regenerative surgery products for pain management in orthopedic centers and clinics. Due to an increasing number of ASCs, the segment of ambulatory surgery centers is expected to increase significantly in the next years. According to the CMS March 2021 data, there are approximately 817 Medicare-certified ASCs located in California, 187 in Washington and 457 in Florida. There are also 442 in Texas, 368 in Georgia, and 457 in Florida. These numbers will likely increase over the next few years.

Regional Insights

North America was the dominant market for orthopedic regenerative surgical instruments in 2020, with a 40.0% revenue share. This is due to key players, an aging population and technologically advanced healthcare facilities in Canada and the U.S. Statistics Canada reported that the country had more than 6.8 million seniors in July 2020. The median age was 40.9. Europe accounted for the second largest share, owing to the high prevalence of orthopedic conditions and growing geriatric populations. This raises the risk of developing orthopaedic disorders, which in turn fuels the demand for orthopedic regenerative surgery products.

The market for orthopedic regenerative surgery products in Asia Pacific is expected to grow at 5.1% annually over the forecast period. This is due to the development of healthcare infrastructure, regional expansion and rising incidence of orthopedic conditions such as osteoarthritis. According to the Ministry of Health and Family Welfare of India, osteoarthritis prevalence in India is between 22% and 39%. This number is expected to rise over time. The Australian Institute of Health and Welfare, Government of Australia reports that 1 in 7 adults suffer from some type of arthritis. 1 in 2 Australians experience moderate to severe pain.

Market Share Insights & Key Companies

The market for orthopedic regenerative surgery products is competitive. Strategic initiatives are implemented by market players, which include R&D, product launches and development, regional expansion and the expansion of distribution networks. Partnerships, mergers and acquisitions are also key players. MiMedx, for example, partnered with Wake Forest Institute For Regenerative Medicine in May 2021 to conduct research and develop new biologics and regenerative science. This was a support to the company's efforts to show that amniotic tissue can be used to treat chronic conditions, including musculoskeletal problems. The following are some of the most prominent players in the market for orthopedic regenerative surgery products:

• Anika Therapeutics, Inc.

• Vericel Corporation

• Baxter

• Zimmer Biomet

• Stryker

• Smith+Nephew

• AlloSource

• Amniox Medical, Inc.

• VSY Biotechnology

• Aptissen S.A

• MiMedx

Up Market Research published a new report titled “Orthopedic Regenerative Surgical Products Market research report which is segmented by End User (Ambulatory Surgical Centers, Hospitals), by Product (Cell-based, Synthetic, Allograft, Viscosupplements), By Players/Companies Zimmer Biomet, Vericel Corporation, Amniox Medical Inc, Stryker, AlloSource, Aptissen SA, Baxter, MiMedx, Smith+Nephew, VSY Biotechnology, Anika Therapeutics Inc”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.

Report Scope

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.

Global Orthopedic Regenerative Surgical Products Market Report Segments:

The market is segmented by End User (Ambulatory Surgical Centers, Hospitals), by Product (Cell-based, Synthetic, Allograft, Viscosupplements).

Orthopedic Regenerative Surgical Products Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

Key Benefits for Industry Participants & Stakeholders:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Orthopedic Regenerative Surgical Products Market

Overview of the regional outlook of the Orthopedic Regenerative Surgical Products Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.

Highlights of The Orthopedic Regenerative Surgical Products Market Report:

1. The market structure and projections for the coming years.
2. Drivers, restraints, opportunities, and current trends of Orthopedic Regenerative Surgical Products Market.
3. Historical data and forecast.
4. Estimations for the forecast period 2028.
5. Developments and trends in the market.

                1. Ambulatory Surgical Centers

                2. Hospitals

                1. Cell-based

                2. Synthetic

                3. Allograft

                4. Viscosupplements

8. Market scenario by region, sub-region, and country.
9. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
10. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
11. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Orthopedic Regenerative Surgical Products Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

How you may use our products:

• Correctly Positioning New Products
• Market Entry Strategies
• Business Expansion Strategies
• Consumer Insights
• Understanding Competition Scenario
• Product & Brand Management
• Channel & Customer Management
• Identifying Appropriate Advertising Appeals

Reasons to Purchase the Orthopedic Regenerative Surgical Products Market Report:

• The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
• Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
• Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
• The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
• Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.